​
​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals stock forecast is as follows: an average price target of $55.20 (represents a -5.64% downside from RYTM’s last price of $58.50) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

RYTM Price Target

The average price target for Rhythm Pharmaceuticals (RYTM) is $55.20 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $64.00 to $25.00. This represents a potential -5.64% downside from RYTM's last price of $58.50.

RYTM Analyst Ratings

Buy

According to 9 Wall Street analysts, Rhythm Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RYTM stock is 0 'Strong Buy' (0.00%), 9 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Rhythm Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Alan CarrNeedham$64.00$55.7814.73%9.40%
Nov 06, 2024Corinne JenkinsGoldman Sachs$59.00$55.785.76%0.85%
Sep 18, 2024Raghuram SelvarajuH.C. Wainwright$64.00$53.1720.37%9.40%
Sep 17, 2024Jonathan WollebenJMP Securities$64.00$54.0018.52%9.40%
Jul 25, 2024Alan CarrNeedham$55.00$49.6110.86%-5.98%
Nov 10, 2022-Goldman Sachs$35.00$24.6841.82%-40.17%
Aug 07, 2022Corinne JenkinsGoldman Sachs$28.00$20.2438.34%-52.14%
Jul 12, 2022Corinne JenkinsGoldman Sachs$6.00$6.38-5.96%-89.74%
Jun 17, 2022-Needham$25.00$3.90541.03%-57.26%
Jun 17, 2022Dae Gon HaStifel Nicolaus$25.00$3.90541.03%-57.26%
Row per page
Go to

The latest Rhythm Pharmaceuticals stock forecast, released on Nov 06, 2024 by Alan Carr from Needham, set a price target of $64.00, which represents a 14.73% increase from the stock price at the time of the forecast ($55.78), and a 9.40% increase from RYTM last price ($58.50).

Rhythm Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts245
Avg Price Target$61.50$62.75$61.20
Last Closing Price$58.50$58.50$58.50
Upside/Downside5.13%7.26%4.62%

In the current month, the average price target of Rhythm Pharmaceuticals stock is $61.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 5.13% increase as opposed to Rhythm Pharmaceuticals's last price of $58.50. This month's average price target is down -1.99% compared to last quarter, and up 0.49% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024Cowen & Co.BuyBuyHold
Nov 06, 2024Goldman SachsBuyBuyHold
Oct 21, 2024Guggenheim-BuyInitialise
Sep 18, 2024NeedhamMarket OutperformMarket OutperformHold
Sep 18, 2024H.C. Wainwright-BuyInitialise
Sep 17, 2024JMP Securities-OutperformInitialise
Sep 17, 2024JMP Securities-Market OutperformInitialise
Jul 25, 2024NeedhamBuyBuyHold
Feb 22, 2024Wells FargoBuyBuyHold
Dec 19, 2023Morgan StanleyEqual-WeightOverweightUpgrade
Row per page
Go to

Rhythm Pharmaceuticals's last stock rating was published by Cowen & Co. on Nov 06, 2024. The company gave RYTM a "Buy" rating, the same as its previous rate.

Rhythm Pharmaceuticals Financial Forecast

Rhythm Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue---------$22.50M$19.22M$11.47M$8.79M$4.28M$9.07M$1.50M$1.82M$1.03M$274.00K$35.00K--
Avg Forecast$51.59M$45.57M$41.86M$38.35M$36.13M$32.52M$28.79M$26.90M$25.38M$22.18M$15.03M$12.12M$7.22M$4.76M$2.57M$2.30M$1.70M$934.20K$551.00K$49.90M$60.00K$500.00K
High Forecast$53.15M$46.94M$43.13M$39.10M$37.84M$32.62M$28.79M$26.90M$27.26M$23.38M$15.48M$12.49M$7.44M$4.76M$2.57M$2.30M$1.70M$934.20K$551.00K$49.90M$60.00K$500.00K
Low Forecast$50.07M$44.22M$40.63M$37.29M$34.87M$32.42M$28.79M$26.90M$23.88M$21.00M$14.58M$11.76M$7.01M$4.76M$2.57M$2.30M$1.70M$934.20K$551.00K$49.90M$60.00K$500.00K
# Analysts4446943478544343545454
Surprise %---------1.01%1.28%0.95%1.22%0.90%3.53%0.65%1.07%1.10%0.50%0.00%--

Rhythm Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 7 analysts is $25.38M, with a low forecast of $23.88M, and a high forecast of $27.26M. RYTM's average Quarter revenue forecast represents a 12.78% increase compared to the company's last Quarter revenue of $22.50M (Sep 23).

Rhythm Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4446943478544343545454
EBITDA---------$-40.65M$-46.60M$-49.12M$-39.48M$-38.27M$-45.10M$-52.34M$-42.54M$-43.79M$-40.09M$65.96M$-34.72M$-33.65M
Avg Forecast$-10.32M$-9.11M$-8.37M$-7.67M$-7.23M$-6.50M$-5.76M$-5.38M$-5.08M$-4.44M$-3.01M$-2.42M$-1.44M$-952.26K$-513.11K$-460.04K$-340.43K$-186.84K$-110.20K$-9.98M$-12.00K$-100.00K
High Forecast$-10.01M$-8.84M$-8.13M$-7.46M$-6.97M$-6.48M$-5.76M$-5.38M$-4.78M$-4.20M$-2.92M$-2.35M$-1.40M$-952.26K$-513.11K$-460.04K$-340.43K$-186.84K$-110.20K$-9.98M$-12.00K$-100.00K
Low Forecast$-10.63M$-9.39M$-8.63M$-7.82M$-7.57M$-6.52M$-5.76M$-5.38M$-5.45M$-4.68M$-3.10M$-2.50M$-1.49M$-952.26K$-513.11K$-460.04K$-340.43K$-186.84K$-110.20K$-9.98M$-12.00K$-100.00K
Surprise %---------9.16%15.51%20.26%27.35%40.19%87.89%113.78%124.96%234.36%363.83%-6.61%2893.49%336.46%

5 analysts predict RYTM's average Quarter EBITDA for Jun 21 to be $-110.20K, with a high of $-110.20K and a low of $-110.20K. This is -100.17% lower than Rhythm Pharmaceuticals's previous annual EBITDA (Mar 21) of $65.96M.

Rhythm Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4446943478544343545454
Net Income---------$-44.16M$-46.70M$-51.83M$-42.88M$-42.45M$-44.91M$-52.84M$-42.87M$-35.11M$-35.39M$43.75M$-34.90M$-33.82M
Avg Forecast$-41.28M$-44.06M$-45.18M$-47.42M$-45.90M$-49.25M$-43.40M$-144.25M$-43.19M$-45.30M$-48.84M$-43.93M$-49.52M$-60.94M$-58.27M$-61.83M$-55.70M$-49.22M$-42.94M$43.75M$-48.12M$-48.28M
High Forecast$-39.69M$-42.36M$-43.45M$-41.80M$-25.43M$-47.36M$-41.73M$-138.71M$-40.73M$-37.55M$-46.96M$-42.24M$-47.62M$-60.94M$-58.27M$-61.83M$-55.70M$-49.22M$-42.94M$52.50M$-48.12M$-48.28M
Low Forecast$-42.90M$-45.79M$-46.96M$-50.54M$-63.89M$-51.19M$-45.10M$-149.91M$-47.51M$-57.82M$-50.76M$-45.65M$-51.47M$-60.94M$-58.27M$-61.83M$-55.70M$-49.22M$-42.94M$35.00M$-48.12M$-48.28M
Surprise %---------0.97%0.96%1.18%0.87%0.70%0.77%0.85%0.77%0.71%0.82%1.00%0.73%0.70%

Rhythm Pharmaceuticals's average Quarter net income forecast for Jun 21 is $-42.94M, with a range of $-42.94M to $-42.94M. RYTM's average Quarter net income forecast represents a -198.14% decrease compared to the company's last Quarter net income of $43.75M (Mar 21).

Rhythm Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4446943478544343545454
SG&A---------$30.48M$30.05M$24.63M$26.32M$21.94M$22.33M$21.45M$21.00M$17.51M$15.46M$14.52M$13.12M$11.29M
Avg Forecast$300.51M$265.43M$243.85M$223.39M$210.44M$189.45M$167.70M$156.67M$147.84M$129.19M$87.54M$70.59M$42.05M$27.73M$14.94M$13.40M$9.92M$5.44M$3.21M$14.52M$349.50K$2.91M
High Forecast$309.59M$273.44M$251.22M$227.76M$220.45M$190.03M$167.70M$156.67M$158.76M$136.18M$90.19M$72.73M$43.32M$27.73M$14.94M$13.40M$9.92M$5.44M$3.21M$17.42M$349.50K$2.91M
Low Forecast$291.64M$257.59M$236.65M$217.22M$203.10M$188.87M$167.70M$156.67M$139.10M$122.31M$84.96M$68.51M$40.81M$27.73M$14.94M$13.40M$9.92M$5.44M$3.21M$11.61M$349.50K$2.91M
Surprise %---------0.24%0.34%0.35%0.63%0.79%1.49%1.60%2.12%3.22%4.82%1.00%37.54%3.88%

Rhythm Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $147.84M, based on 7 Wall Street analysts, with a range of $139.10M to $158.76M. The forecast indicates a 385.12% rise compared to RYTM last annual SG&A of $30.48M (Sep 23).

Rhythm Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4446943478544343545454
EPS---------$-0.76$-0.82$-0.91$-0.76$-0.83$-0.89$-1.05$-0.85$-0.70$-0.70$0.92$-0.79$-0.77
Avg Forecast$-0.67$-0.72$-0.74$-0.77$-0.75$-0.80$-0.71$-2.36$-0.71$-0.74$-0.80$-0.72$-0.81$-1.00$-0.95$-1.01$-0.91$-0.81$-0.70$0.30$-0.79$-0.79
High Forecast$-0.65$-0.69$-0.71$-0.68$-0.42$-0.77$-0.68$-2.27$-0.67$-0.61$-0.77$-0.69$-0.78$-1.00$-0.95$-1.01$-0.91$-0.81$-0.70$0.30$-0.79$-0.79
Low Forecast$-0.70$-0.75$-0.77$-0.83$-1.04$-0.84$-0.74$-2.45$-0.78$-0.94$-0.83$-0.75$-0.84$-1.00$-0.95$-1.01$-0.91$-0.81$-0.70$0.30$-0.79$-0.79
Surprise %---------1.03%1.03%1.27%0.94%0.83%0.93%1.04%0.93%0.87%0.99%3.08%1.00%0.97%

According to 5 Wall Street analysts, Rhythm Pharmaceuticals's projected average Quarter EPS for Jun 21 is $-0.70, with a low estimate of $-0.70 and a high estimate of $-0.70. This represents a -176.49% decrease compared to RYTM previous annual EPS of $0.92 (Mar 21).

Rhythm Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$1.77$33.861812.99%Buy
QUREuniQure$6.18$53.67768.45%Buy
BDTXBlack Diamond Therapeutics$2.50$14.75490.00%Buy
INZYInozyme Pharma$2.88$14.67409.38%Buy
RLAYRelay Therapeutics$4.89$19.40296.73%Buy
SLDBSolid Biosciences$5.00$17.50250.00%Buy
RCKTRocket Pharmaceuticals$13.66$45.20230.89%Buy
PLRXPliant Therapeutics$12.32$39.71222.32%Buy
ARVNArvinas$23.19$71.82209.70%Buy
STOKStoke Therapeutics$11.88$30.60157.58%Buy
CGEMCullinan Oncology$13.45$31.50134.20%Buy
SNDXSyndax Pharmaceuticals$16.11$34.30112.91%Buy
VRDNViridian Therapeutics$20.34$37.9286.43%Buy
KNSAKiniksa Pharmaceuticals$21.50$36.3368.98%Buy
AKROAkero Therapeutics$29.56$46.0055.62%Buy
MGTXMeiraGTx$6.09$9.0047.78%Buy
RNAAvidity Biosciences$41.35$54.5031.80%Buy
NUVLNuvalent$87.69$111.5727.23%Buy
PTGXProtagonist Therapeutics$40.39$50.0023.79%Buy
RVMDRevolution Medicines, Inc. Warrant$54.24$60.6311.78%Buy
RYTMRhythm Pharmaceuticals$58.50$55.20-5.64%Buy
ACLXArcellx$88.22$83.00-5.92%Buy

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals a good buy?

Yes, according to 9 Wall Street analysts, Rhythm Pharmaceuticals (RYTM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 100.00% of RYTM's total ratings.

What is RYTM's price target?

Rhythm Pharmaceuticals (RYTM) average price target is $55.2 with a range of $25 to $64, implying a -5.64% from its last price of $58.5. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Rhythm Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for RYTM stock, the company can go down by -5.64% (from the last price of $58.5 to the average price target of $55.2), up by 9.40% based on the highest stock price target, and down by -57.26% based on the lowest stock price target.

Can Rhythm Pharmaceuticals stock reach $90?

RYTM's average twelve months analyst stock price target of $55.2 does not support the claim that Rhythm Pharmaceuticals can reach $90 in the near future.

What is Rhythm Pharmaceuticals's current price target trend?

2 Wall Street analysts forecast a $61.5 price target for Rhythm Pharmaceuticals (RYTM) this month, up 5.13% from its last price of $58.5. Compared to the last 3 and 12 months, the average price target increased by 7.26% and increased by 4.62%, respectively.

What are Rhythm Pharmaceuticals's analysts' financial forecasts?

Rhythm Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $124.33M (high $126.15M, low $122.98M), average EBITDA is $-24.867M (high $-24.595M, low $-25.231M), average net income is $-283M (high $-253M, low $-310M), average SG&A $724.26M (high $734.85M, low $716.34M), and average EPS is $-4.619 (high $-4.137, low $-5.065). RYTM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $177.37M (high $182.32M, low $172.2M), average EBITDA is $-35.474M (high $-34.441M, low $-36.464M), average net income is $-178M (high $-167M, low $-186M), average SG&A $1.03B (high $1.06B, low $1B), and average EPS is $-2.907 (high $-2.733, low $-3.041).

Did the RYTM's actual financial results beat the analysts' financial forecasts?

Based on Rhythm Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $77.43M, beating the average analysts forecast of $74.71M by 3.64%. Apple's EBITDA was $-184M, beating the average prediction of $-14.941M by 1133.89%. The company's net income was $-185M, beating the average estimation of $-181M by 1.88%. Apple's SG&A was $117.53M, missing the average forecast of $435.16M by -72.99%. Lastly, the company's EPS was $-0.0032, missing the average prediction of $-2.961 by -99.89%. In terms of the last quarterly report (Sep 2023), Rhythm Pharmaceuticals's revenue was $22.5M, beating the average analysts' forecast of $22.18M by 1.47%. The company's EBITDA was $-40.646M, beating the average prediction of $-4.436M by 816.36%. Rhythm Pharmaceuticals's net income was $-44.163M, missing the average estimation of $-45.303M by -2.52%. The company's SG&A was $30.48M, missing the average forecast of $129.19M by -76.41%. Lastly, the company's EPS was $-0.76, beating the average prediction of $-0.74 by 2.70%